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Abstract
Objectives—Chronic migraine (CM), pre-
viously called transformed migraine, is a
frequent headache disorder that aVects
2%-3% of the general population. Analge-
sic overuse, insomnia, depression, and
anxiety are disorders that are often co-
morbid with CM. Hypothalamic dysfunc-
tion has been implicated in its
pathogenesis, but it has never been stud-
ied in patients with CM. The aim was to
analyze hypothalamic involvement in CM
by measurement of melatonin, prolactin,
growth hormone, and cortisol nocturnal
secretion.
Methods—A total of 338 blood samples
(13/patient) from 17 patients with CM and
nine age and sex matched healthy volun-
teers were taken. Melatonin, prolactin,
growth hormone, and cortisol concentra-
tions were determined every hour for 12
hours. The presence of comorbid disor-
ders was also evaluated.
Results—An abnormal pattern of hy-
pothalamic hormonal secretion was found
in CM. This included: (1) a decreased
nocturnal prolactin peak, (2) increased
cortisol concentrations, (3) a delayed noc-
turnal melatonin peak in patients with
CM, and (4) lower melatonin concentra-
tions in patients with CM with insomnia.
Growth hormone secretion did not diVer
from controls.
Conclusion—These results support hy-
pothalamic involvement in CM, shown by
a chronobiologic dysregulation, and a
possible hyperdopaminergic state in pa-
tients with CM. Insomnia might be an
important variable in the study findings.
(J Neurol Neurosurg Psychiatry 2001;71:747–751)
Keywords: chronic migraine; prolactin; cortisol; mela-
tonin; hypothalamus
Chronic migraine (CM) is a debilitating disor-
der that aVects 2.4% of the general population1
and accounts for most consultations in head-
ache clinics—40%2 to 65%.3 Because CM
aVects people during their peak productive
years, it imposes a significant decrease in their
quality of life and considerable economical
burden to society.4
Patients with CM often have a history of epi-
sodic migraine beginning in their teenage
years. The headache frequency increases over
months or years, and the associated symptoms
of nausea, vomiting, photophobia, and phono-
phobia become less prominent.5 Chronic mi-
graine is a complex syndrome with many asso-
ciated conditions including acute medication
overuse,6 generalised anxiety disorder (70%),7
major depression (80%),7 and insomnia
(71%).8
Little is known about the causes and mecha-
nisms of CM. The transformation of episodic
migraine to CM (>15 days/month) remains an
enigma. Several mechanisms have been alleged
to be the cause of the change in frequency and
symptoms, including chronic neurogenic in-
flammation, central sensitisation, defective
central pain modulation, hypothalamic dys-
function, or a combination of these.
Hypothalamic involvement in the pathogen-
esis of cluster headache is well known,9 whereas
the role of the hypothalamus in the pathophysi-
ology of chronic migraine has never been stud-
ied. For this reason we chose to explore the
hypothalamic-tuberoinfundibular system (pro-
lactin, growth hormone), the hypothalamic-
hypophyseal-adrenal axis (cortisol), and pineal
gland function (melatonin) in CM.
Material and methods
A study was performed from February to April
1999, at Sao Paulo Federal University Head-
ache Clinic. A total of 26 subjects were enrolled
in the study. All subjects provided written con-
sent for the experimental procedure approved
by the Sao Paulo federal university ethics com-
mittee. Seventeen patients, 14 women and
three men, aged 31 (SD 9) met the criteria of
Silberstein and Lipton6 for CM. Nine healthy
volunteers, seven women and two men, aged 29
(SD 6), also participated in the study as
controls.
Eleven of the patients were overusing
analgesic drugs (nine were overusing dipyrone,
three caVeine, two isometeptene, two acetyl-
salicilic acid, two acetaminophen, and two
ergotamine. Four were diagnosed with fibro-
myalgia and eight with insomnia (table 1).
All patients with CM were instructed not to
take acute medication more than 2 or 3 days a
week during the week before the blood
determination. None had taken any preventive
medication for at least 3 months before the
study. None had hypertension, alcoholism, or
history of any relevant medical disease, and
none smoked. Hormone concentrations were
determined within 1 week after enrollment.
Subjects were admitted to hospital and kept
under controlled environmental luminosity
conditions not exceeding 50 Lux. A venous line
was placed at 1800 and blood samples were
taken every hour from 1900 to 0700. A total of
13 samples/subject were collected. Women’s
samples were obtained during the follicular
phase of the menstrual cycle.
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Concentrations of hormones were deter-
mined in each blood sample by radioimmu-
noassay The intra-assay and interassay coeY-
cients of variation (CVs ) for the assays were as
follows: prolactin 4% and 7%; cortisol 4% and
6%; growth hormone 5% and 8%; and
melatonin 6% and 10% respectively. Four
patients did not have growth hormone
measured, two because their body mass index
was greater than 30, and two because they were
21 years of age or younger (table 1).
Depression was assessed by the Beck depres-
sion inventory II,10 and anxiety by the trait and
state anxiety inventory.11 The American Col-
lege of Rheumatology diagnostic criteria were
used for the diagnosis of fibromyalgia.12
Patients were diagnosed with insomnia accord-
ing to the criteria shown:
x DiYculty of sleep onset or maintenance
x Insomnia at least three times a week for at
least 1 month
x Insomnia interfering with daily personal
functioning
x Patient fulfills the proposed diagnostic crite-
ria of Silberstein and Lipton6 for CM.
ANALYSIS
The time of peak, peak concentration, area
under the curve (AUC), and the average of 13
samples in patients versus controls for each
hormone were analyzed. We also accounted for
other variables such as depression, anxiety,
analgesic overuse, insomnia, and fibromyalgia.
A phase delay in the melatonin nocturnal peak
was considered if the time of the peak occurred
after 0300.13
The Mann-Whitney rank sum test and
student’s t test were used to compare the
means, peak concentrations, and AUCs be-
tween subgroups (depression, anxiety, analge-
sic overuse, insomnia, and fibromyalgia). Fish-
er’s exact test was used for the time of peak
analysis. Analysis of variance (ANOVA) with
repeated measures was used to compare
patients and controls. Pearson’s test was used
for the correlation analysis. Values are ex-
pressed as means (SD). The level of signifi-
cance was taken as p<0.05.
Results
MELATONIN
Eight patients with CM (47%) had a phase
delay in the melatonin peak whereas none of
the controls had (p<0.05, fig 1). There was no
significant diVerence in nocturnal melatonin
secretion between patients and controls (40.3
(19.1) v 43.2 (16.0) pg/ml, respectively).
Patients who had CM plus insomnia (n=8)
had melatonin concentrations (28.0 (19.9)
pg/ml), AUC (347.5 (128.6) pg.h/ml), and
peak concentration (50.3 (19.6) pg/ml) that
were significantly lower than those in patients
with CM without insomnia (51.9 (10.3) pg/ml;
643.3 (238.0) pg.h/ml, and 111.9 (45.7) pg/ml,
respectively, all p<0.05) and that were also sig-
nificantly lower than those in controls. There
was no diVerence in time of peak or in the pro-
lactin, cortisol, or growth hormone concentra-
tions and between patients with and without
nocturnal melatonin phase delay.
PROLACTIN
Fifty three per cent of patients had peak
concentrations of prolactin lower than 25
ng/ml (18 (3) ng/ml), but only two of the nine
controls did (15.6 ng/ml) (p<0.05; fig 2)). The
mean concentration of prolactin in patients
with CM was not significantly diVerent from
controls (26 (11) ng/ml v 37 (17) ng/ml
respectively, p=0.06). There was no significant
diVerence in the mean prolactin peak in
patients with CM with or without analgesic
overuse (23 (8) v 31 (13) ng/ml). There was no
Table 1 Clinical characteristics of the patients
CM
patient Age Sex
Years of
CM Fibromyalgia Insomnia Analgesic overuse
1 27 F 0.25 −
2 21 M 0.86 −
3 25 F 2 +
4 28 F 2 Aspirin, caVeine
5 47 F 16 + Ergotamine, dipirone
6 16 F 4 −
7 34 M 20 + −
8 25 F 3 + + Dipirone
9 35 F 10 + Dipirone, aspirin, acetaminophen
10 23 F 5 Dipirone
11 37 F 6 + + Dipirone, caVeine
12 28 F 3 + Ergotamine, acetaminophen
13 38 M 20 + + −
14 46 F 20 Dipirone
15 26 F 1 Dipirone, isomepthene
16 44 F 30 + Dipirone, caVeine, aspirin
17 27 F 10 Dipirone, isomepthene
Controls
18 28 F − − − −
19 31 F − − − −
20 22 M − − − −
21 44 F − − − −
22 24 F − − − −
23 29 F − − − −
24 27 F − − − −
25 30 F − − − −
26 27 M − − − −
Figure 1 Melatonin nocturnal profile in patients with
CM v controls and patients with CM with insomnia v
without insomnia.
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significant diVerence in the mean or AUC
between patients and controls or between
patients with or without analgesic overuse and
with or without insomnia.
CORTISOL
Patients had higher cortisol concentrations
than controls (10.3 (4.3) v 6.7 (1.2) µg/dl;
higher AUC (101.7 (49.0) v 76.6 (14.3) µg.h/
dl); and higher peak (22.5 (14.2) v 18.6 (4.1)
µg/dl); all p<0.05, fig 2)). There were no
significant diVerences between patients with or
without insomnia, drug overuse, or fibromyal-
gia.
There was an increase in cortisol concentra-
tion between 2300 and 0100 that deviated
from the expected pattern with respect to con-
trols, although this increase did not reach
significance.
GROWTH HORMONE
There was no diVerence between patients and
controls in growth hormone secretion (mean
2.0 (1.2) v 2.9 (1.9) ng/dl, respectively).
Repetitive measure analysis failed to show any
significant diVerence. Analysis of the sub-
groups did not show any diVerence in concen-
trations or time of peak.
Discussion
Prolactin, growth hormone, cortisol, and mela-
tonin concentrations were determined every
hour for 12 hours to investigate the role of the
hypothalamus in chronic migraine. The hor-
mones were measured during the night as the
highest concentrations are usually at this time.
We found decreased prolactin peak secretion,
increased cortisol concentrations, a phase delay
in the melatonin peak, and lower melatonin
concentrations in patients with CM with
insomnia.
MELATONIN
Lower melatonin concentrations have been
reported in episodic migraine, menstrual mi-
graine, and cluster headache. This is the first
study of melatonin in patients with CM.
Forty seven per cent of patients with CM
had a significant phase delay in the melatonin
peak, and half had insomnia. Melatonin
concentrations, peak secretion, and AUCs were
significantly lower in patients with CM who
had insomnia than in controls and patients
with CM without insomnia.
Lower melatonin concentrations, but not a
phase shift in the nocturnal peak, have been
reported in patients with insomnia.14 A phase
delay in the nocturnal melatonin peak has been
reported in patients with delayed sleep phase
syndrome (DSPS),15 and these patients treated
with 5 mg melatonin had a great improvement
of both sleep and its associated headaches.16
The circadian rhythm of melatonin secretion
is regulated by the suprachiasmatic nucleus in
the hypothalamus.17 The phase delay in the
melatonin peak found in patients with CM
supports the theory that hypothalamic involve-
ment in CM leads to a chronobiological
dysfunction; however, it is not known whether
it is a cause or a consequence of the disease. It
could also be due to an underlying delayed
sleep phase syndrome and other sleep disorder
comorbidity.
Melatonin is a potent endogenous scavenger
of reactive oxygen species acting as a neuropro-
tective agent in processes involving free radical
formation and excitatory amino acid release.18
Evidence in laboratory animals shows that this
neuroprotective action is probably mediated
through inhibition of NF-kappaB, a peptide
upstream of tumour necrosis factor (TNFá),
which is known to be involved in inflammatory
processes and sensitisation19 It is hypothesised
that dysfunction in melatonin secretion can
favour sensitisation and persistence of inflam-
matory products. Melatonin receptors have
also been found in cerebral arteries and in the
hypothalamus.20
Melatonin may have a role in the treatment
of CM, particularly in those patients with
insomnia, but further studies are necessary to
confirm this. Its other favourable qualities for
CM treatment include its analgesic proper-
ties,21 and the fact that it potentiates a GABA
inhibitory eVect22 and inhibits prostaglandin E
synthesis.23 Melatonin is a sensitive marker of
endogenous rhythms24 and is thought to play an
important part in the adaptative mechanisms
to changing enviromental and endogenous
stimuli.25
PROLACTIN
Patients with chronic migraine show a de-
creased nocturnal prolactin peak. Studies have
reported normal prolactin values in episodic
migraine,26–29 but none of them analyzed the
Figure 2 Prolactin and cortisol nocturnal profile in
patients with CM v controls.
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nocturnal prolactin profile. This is the first
study on prolactin concentrations in CM.
Based on the hypersensitivity of dopamine
receptors that some migraineurs manifest,
modulating dopaminergic neurotransmission
has been a therapeutic target. This is demon-
strated by the induction of yawning, nausea,
vomiting, and hypotension by dopaminergic
agonists.30 31 In addition, some migraineurs
show allelic variations within the DRD2 gene
that has been hypothesised to predispose to a
hypersensitive state to dopamine.32 Prolactin
secretion is one measure of dopaminergic
function, as dopamine is its main inhibitory
factor. The measurement of prolactin can indi-
rectly provide information on the dopaminer-
gic system in CM.
We hypothesise that there is a sustained noc-
turnal inhibition of prolactin by dopamine and,
therefore, an indirect increase in dopamine
secretion. Many antidopaminergic agents have
been successfully used in acute (droperidol,33 34
chlorpromazine,35 prochlorperazine,36 metoclo-
pramide, domperidone,37 haloperidol38), and
preventive (flunarizine,39 olanzapine (personal
communication)) headache treatment. Our
findings support the use of these drugs in CM,
but clinical trials are needed to confirm their
eYcacy.
Tumour necrosis factor-á, a potent proin-
flammatory cytokine involved in pain and
inflammatory disorders such as multiple scle-
rosis,40 psoriasis,41 meningitis,42 and migraine,43
has been shown to inhibit prolactin release. Its
algesic eVects are due to sensitising actions on
nociceptive aVerents, upregulation of other
proinflammatory and algesic proteins, and a
triggering of cyclooxygenase dependent path-
ways to synthesise prostaglandins. If we con-
sider neurogenic inflammation as part of the
pathogenesis of migraine, it is possible that the
suppressed peak of prolactin could also be due
to an increase in TNFá.
CORTISOL
Cortisol concentrations are raised in many
conditions related to CM, such as depression,44
anxiety,45 insomnia,46 fibromyalgia,47 and
chronic pain.48 This is the first study of cortisol
concentrations in patients with CM. We found
higher concentrations of cortisol, suggesting
that the hypophyseal-adrenal axis is activated
in patients with CM compared with controls.
Glucocorticoids exert numerous eVects on
metabolism, inflammation, and immunity,49
and play an important part in pain inhibitory
mechanisms.50
It is also important to consider the long term
eVect of a hypercortisol state in patients with
CM. Arterial hypertension was found by
Mathew8 in the transformation of episodic to
chronic daily headache. The increase in
cortisol concentrations could be the biological
basis for this finding, although patients with
hypertension were excluded from our study.
Cortisol concentrations should be studied in
patients with CM and arterial hypertension in
the future.
GROWTH HORMONE
Growth hormone regulation is complex; neu-
ropeptides, neurotransmitters, and opioids are
involved. Dopamine also inhibits growth hor-
mone secretion in the hypophysis,51 and the
study of this hormone is another indirect way
to address the dopaminergic system. Our data
did not show any significant diVerence in the
analysis of growth hormone. However, any dif-
ferences may not have been great enough to be
detected with the small sample studied. The
role of growth hormone in headaches remains
unknown.
Conclusion
We found an abnormal pattern of hypotha-
lamic hormonal secretion in CM. This com-
prised: (1) a decreased nocturnal prolactin
peak, (2) increased cortisol concentrations, (3)
a delayed nocturnal melatonin peak in patients
with CM, and (4) lower melatonin concentra-
tions in patients with CM with insomnia.
Secretion of growth hormone did not diVer
from controls. Overall, these results support
the involvement of the hypothalamus in the
pathophysiology of CM as shown by a chrono-
biological dysregulation, and a possible hyper-
dopaminergic state in patients with CM.
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